Intensity Therapeutics Faces Profit Losses, Stock Decline Amid Cancer‑Research Challenges
Intensity Therapeutics’ steep stock decline and negative P/E reveal challenges for this clinical‑testing firm focused on refractory solid tumor cancers.
3 minutes to read
